Skip to main content
Top
Published in: Clinical Pharmacokinetics 4/2016

01-04-2016 | Systematic Review

Therapeutic Concentrations of Metformin: A Systematic Review

Authors: Farshad Kajbaf, Marc E. De Broe, Jean-Daniel Lalau

Published in: Clinical Pharmacokinetics | Issue 4/2016

Login to get access

Abstract

Background

Metformin has been available since 1957. Over 50 years later, one can legitimately question whether a clear definition of its “therapeutic concentrations” is available.

Objective

The objective of this systematic review was to establish whether or not there is a literature consensus on the “therapeutic concentrations” of metformin.

Methods

We systematically searched the scientific literature with the keywords “metformin”, “therapeutic concentration”, “therapeutic level”, and “therapeutic range”. When the suggested values were defined by citing a literature reference, the types of studies in cited references and the concordance of data between the citations and theirs sources were studied.

Results

We identified 120 documents that reported or cited 65 different “therapeutic” plasma metformin concentrations or ranges. The values ranged from 0.129 to 90 mg/L, and the lowest and highest boundaries were 0 and 1800 mg/L. Only four original research studies determined a “therapeutic concentration”. Fifty-four publications cited previous studies as defining the therapeutic concentrations, whereas 62 publications mentioned “therapeutic concentrations” but did not even cite a supporting reference. The supporting references were mostly reviews, pharmacokinetic studies and in vitro studies. In the 54 publications that cited references, concordance between the wording of the citation and the true nature of the source data was observed in only 23 cases (42.6 %).

Limitations

Given the nature of a systematic literature search, the only possible limitation would be incomplete identification and retrieval of publications on therapeutic concentrations. An extensive study of the literature has, however, been performed by examining nearly 1000 potentially relevant publications.

Guidance for Clinical Practice

The only valid way of defining the therapeutic concentration window for metformin would be to relate dose efficacy (in terms of blood glucose control) to the corresponding plasma concentration in long-term treated patients.

Conclusions

Although metformin has been available for over 50 years and it is the key medication in first-line treatment of type 2 diabetes mellitus, major methodological and/or conceptual errors have confounded the literature on its therapeutic concentrations.
Literature
1.
go back to reference Shargel L, Wu-Pong S, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 5th ed. New York: McGraw-Hill; 2005. p. 613–72. Shargel L, Wu-Pong S, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 5th ed. New York: McGraw-Hill; 2005. p. 613–72.
2.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.PubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.PubMedCrossRef
3.
go back to reference Lalau JD, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 2015;87(2):308–22.PubMedCrossRef Lalau JD, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 2015;87(2):308–22.PubMedCrossRef
4.
go back to reference Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.PubMedPubMedCentralCrossRef Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.PubMedPubMedCentralCrossRef
5.
go back to reference Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.PubMed Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.PubMed
7.
go back to reference Frayn KN, Adnitt PI. Effects of metformin on glucose uptake by isolated diaphragm from normal and diabetic rats. Biochem Pharmacol. 1972;21(23):3153–62.PubMedCrossRef Frayn KN, Adnitt PI. Effects of metformin on glucose uptake by isolated diaphragm from normal and diabetic rats. Biochem Pharmacol. 1972;21(23):3153–62.PubMedCrossRef
8.
go back to reference Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.PubMedCrossRef Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.PubMedCrossRef
9.
go back to reference Pignard P. Spectrophotometric determination of N,N-dimethylbiguanide in blood and urine [in French]. Ann Biol Clin (Paris). 1962;20:325–33. Pignard P. Spectrophotometric determination of N,N-dimethylbiguanide in blood and urine [in French]. Ann Biol Clin (Paris). 1962;20:325–33.
10.
go back to reference Adnitt PI, Frayn KN. Effects of metformin on glucose uptake by the isolated rat diaphragm. Br J Pharmacol. 1972;45(1):152P–3P.PubMedPubMedCentral Adnitt PI, Frayn KN. Effects of metformin on glucose uptake by the isolated rat diaphragm. Br J Pharmacol. 1972;45(1):152P–3P.PubMedPubMedCentral
11.
go back to reference Clarke BF, Ducan LJP. Biguanide treatment in the management of insulin independent (maturity-onset) diabetes: clinical experience with metformin. Res Clin Forums. 1979;1:53–63. Clarke BF, Ducan LJP. Biguanide treatment in the management of insulin independent (maturity-onset) diabetes: clinical experience with metformin. Res Clin Forums. 1979;1:53–63.
12.
go back to reference Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24(6):683–93.PubMedCrossRef Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24(6):683–93.PubMedCrossRef
13.
go back to reference Isnard F, Laviuville M, Gut M. Pharmacocinétique de la metformine. In: Journées de Diabétologie de l’Hôtel-Dieu. Paris: Flammarion Médecine-Sciences; 1980. p. 305–12. Isnard F, Laviuville M, Gut M. Pharmacocinétique de la metformine. In: Journées de Diabétologie de l’Hôtel-Dieu. Paris: Flammarion Médecine-Sciences; 1980. p. 305–12.
14.
go back to reference Bruneder H, Klein HJ, Isnard F, Noel M. Fasting metformin levels in ambulatory treated diabetic patients [abstract]. Excerpta Medica 1979;ICS 481:33,82P. Bruneder H, Klein HJ, Isnard F, Noel M. Fasting metformin levels in ambulatory treated diabetic patients [abstract]. Excerpta Medica 1979;ICS 481:33,82P.
15.
go back to reference Mountjoy KG, Finlay GJ, Holdaway IM. Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro. J Endocrinol Invest. 1987;10(6):553–7.PubMedCrossRef Mountjoy KG, Finlay GJ, Holdaway IM. Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro. J Endocrinol Invest. 1987;10(6):553–7.PubMedCrossRef
16.
go back to reference Lambert H, Isnard F, Delorme N, Claude D, Bollaert PE, Straczek J, Larcan A. Physiopathological approach to pathological hyperlactatemia in the diabetic patient. Value of blood metformin [in French]. Ann Fr Anesth Reanim. 1987;6(2):88–94.PubMedCrossRef Lambert H, Isnard F, Delorme N, Claude D, Bollaert PE, Straczek J, Larcan A. Physiopathological approach to pathological hyperlactatemia in the diabetic patient. Value of blood metformin [in French]. Ann Fr Anesth Reanim. 1987;6(2):88–94.PubMedCrossRef
18.
go back to reference Wollen N, Bailey CJ. Metformin potentiates the antigluconeogenic action of insulin. Diabete Metab. 1988;14(2):88–91.PubMed Wollen N, Bailey CJ. Metformin potentiates the antigluconeogenic action of insulin. Diabete Metab. 1988;14(2):88–91.PubMed
19.
go back to reference Beckmann R. Biguanide (Experimenteller Teil). In: Maske H, editor. Handbook of experimental pharmacology, vol. 29. Berlin: Springer; 1971. p. 439–596. Beckmann R. Biguanide (Experimenteller Teil). In: Maske H, editor. Handbook of experimental pharmacology, vol. 29. Berlin: Springer; 1971. p. 439–596.
20.
go back to reference Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums. 1979;1:33–44. Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums. 1979;1:33–44.
21.
go back to reference Caporicci D, Mori A, Pepi R, Lapi E. Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus [in Italian. Clin Ter. 1979;88(4):372–86.PubMed Caporicci D, Mori A, Pepi R, Lapi E. Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus [in Italian. Clin Ter. 1979;88(4):372–86.PubMed
22.
go back to reference De Lorenzi F. La farmacocinetica e la farmacodinamica delle biguanide [in Italian]. Omnia Med Ther. 1975;56. De Lorenzi F. La farmacocinetica e la farmacodinamica delle biguanide [in Italian]. Omnia Med Ther. 1975;56.
23.
go back to reference Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol. 1988;37(22):4353–8.PubMedCrossRef Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol. 1988;37(22):4353–8.PubMedCrossRef
24.
go back to reference Bailey CJ, Nattrass M. Treatment–metformin. Baillieres Clin Endocrinol Metab. 1988;2(2):455–76.PubMedCrossRef Bailey CJ, Nattrass M. Treatment–metformin. Baillieres Clin Endocrinol Metab. 1988;2(2):455–76.PubMedCrossRef
25.
go back to reference Gregorio F, Filipponi P, Ambrosi F, Cristallini S, Marchetti P, Calafiore R, et al. Metformin potentiates B-cell response to high glucose: an in vitro study on isolated perfused pancreas from normal rats. Diabete Metab. 1989;15(3):111–7.PubMed Gregorio F, Filipponi P, Ambrosi F, Cristallini S, Marchetti P, Calafiore R, et al. Metformin potentiates B-cell response to high glucose: an in vitro study on isolated perfused pancreas from normal rats. Diabete Metab. 1989;15(3):111–7.PubMed
26.
go back to reference Benzi L, Marchetti P, Cecchetti P, Navalesi R. Determination of metformin and phenformin in human plasma and urine by RP-HPLC. J Chromatgr Biomed Appl. 1986;48:184–9.CrossRef Benzi L, Marchetti P, Cecchetti P, Navalesi R. Determination of metformin and phenformin in human plasma and urine by RP-HPLC. J Chromatgr Biomed Appl. 1986;48:184–9.CrossRef
27.
go back to reference Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39(11):1831–4.PubMedCrossRef Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39(11):1831–4.PubMedCrossRef
28.
go back to reference Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in the elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxicol. 1990;28(8):329–32.PubMed Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in the elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxicol. 1990;28(8):329–32.PubMed
29.
go back to reference Gregorio F, Ambrosi F, Cristallini S, Marchetti P, Navalesi R, Brunetti P, et al. Do metformin and phenformin potentiate differently B-cell response to high glucose? An in vitro study on isolated rat pancreas. Diabete Metab. 1991;17(1):19–28.PubMed Gregorio F, Ambrosi F, Cristallini S, Marchetti P, Navalesi R, Brunetti P, et al. Do metformin and phenformin potentiate differently B-cell response to high glucose? An in vitro study on isolated rat pancreas. Diabete Metab. 1991;17(1):19–28.PubMed
30.
go back to reference Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–46.PubMedPubMedCentralCrossRef Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–46.PubMedPubMedCentralCrossRef
31.
go back to reference Sarabia V, Lam L, Burdett E, Leiter LA, Klip A. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest. 1992;90(4):1386–95.PubMedPubMedCentralCrossRef Sarabia V, Lam L, Burdett E, Leiter LA, Klip A. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest. 1992;90(4):1386–95.PubMedPubMedCentralCrossRef
32.
go back to reference Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16(3):195–202.PubMedCrossRef Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16(3):195–202.PubMedCrossRef
33.
go back to reference Freisleben HJ, Ruckert S, Wiernsperger N, Zimmer G. The effects of glucose, insulin and metformin on the order parameters of isolated red cell membranes. An electron paramagnetic resonance spectroscopic study. Biochem Pharmacol. 1992;43(6):1185–94.PubMedCrossRef Freisleben HJ, Ruckert S, Wiernsperger N, Zimmer G. The effects of glucose, insulin and metformin on the order parameters of isolated red cell membranes. An electron paramagnetic resonance spectroscopic study. Biochem Pharmacol. 1992;43(6):1185–94.PubMedCrossRef
36.
go back to reference Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med. 1992;9(1):61–5.PubMedCrossRef Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med. 1992;9(1):61–5.PubMedCrossRef
37.
go back to reference Hermann LS, Melander A. Biguanides: Basic aspects and clinical uses. In: Alberti KGM, DeFronzo RA, Keen H, Zimmet P, editors. International textbook of diabetes mellitus, vol. 1. London: Wiley; 1992. p. 773–95. Hermann LS, Melander A. Biguanides: Basic aspects and clinical uses. In: Alberti KGM, DeFronzo RA, Keen H, Zimmet P, editors. International textbook of diabetes mellitus, vol. 1. London: Wiley; 1992. p. 773–95.
38.
go back to reference Marchetti P, Benzi L, Cecchetti P, Giannarelli R, Boni C, Ciociaro D, et al. Plasma biguanide levels are correlated with metabolic effects in diabetic patients. Clin Pharmacol Ther. 1987;41(4):450–4.PubMedCrossRef Marchetti P, Benzi L, Cecchetti P, Giannarelli R, Boni C, Ciociaro D, et al. Plasma biguanide levels are correlated with metabolic effects in diabetic patients. Clin Pharmacol Ther. 1987;41(4):450–4.PubMedCrossRef
39.
go back to reference Marchetti P, Benzi L, Gregorio F, Giannarelli R, Cecchetti P, Di Cianni G, et al. New findings on the metabolic effects of biguanides. In vitro and in vivo studies. Minerva Endocrinol. 1988;13(3):173–80.PubMed Marchetti P, Benzi L, Gregorio F, Giannarelli R, Cecchetti P, Di Cianni G, et al. New findings on the metabolic effects of biguanides. In vitro and in vivo studies. Minerva Endocrinol. 1988;13(3):173–80.PubMed
40.
go back to reference Chalmers J, McBain AM, Brown IRF, Campbell IW. Metformin: Is its use contraindicated in the elderly? Pract Diab Int. 1992;9:51–3.CrossRef Chalmers J, McBain AM, Brown IRF, Campbell IW. Metformin: Is its use contraindicated in the elderly? Pract Diab Int. 1992;9:51–3.CrossRef
41.
go back to reference Bailey CJ. Metformin revisited: its actions and indications for use. Diabetic Med. 1988;5:315–20.PubMedCrossRef Bailey CJ. Metformin revisited: its actions and indications for use. Diabetic Med. 1988;5:315–20.PubMedCrossRef
42.
go back to reference Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia. 1994;37(8):826–32.PubMedCrossRef Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia. 1994;37(8):826–32.PubMedCrossRef
43.
go back to reference Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology. 1994;49(4):260–6.PubMedCrossRef Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology. 1994;49(4):260–6.PubMedCrossRef
44.
go back to reference Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet. 1989;16(2):100–28.PubMedCrossRef Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet. 1989;16(2):100–28.PubMedCrossRef
45.
go back to reference Fischer Y, Thomas J, Rösen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology. 1995;136(2):412–20.PubMed Fischer Y, Thomas J, Rösen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology. 1995;136(2):412–20.PubMed
47.
go back to reference Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 1995;18(6):779–84.PubMedCrossRef Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 1995;18(6):779–84.PubMedCrossRef
48.
go back to reference Miao J, Smoak IW. In vitro effects of the biguanide metformin on early-somite mouse embryos. Toxic Subst Mech. 1995;14(3):185–92. Miao J, Smoak IW. In vitro effects of the biguanide metformin on early-somite mouse embryos. Toxic Subst Mech. 1995;14(3):185–92.
49.
go back to reference Wiernsperger N. Biguanides: preclinical pharmacology. In: Kuhlman J, editor. Handbook of experimental pharmacology, vol. 119. New York: Springer; 1996. p. 305–58. Wiernsperger N. Biguanides: preclinical pharmacology. In: Kuhlman J, editor. Handbook of experimental pharmacology, vol. 119. New York: Springer; 1996. p. 305–58.
50.
go back to reference Stith BJ, Goalstone ML, Espinoza R, Mossel C, Roberts D, Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinology. 1996;137(7):2990–9.PubMed Stith BJ, Goalstone ML, Espinoza R, Mossel C, Roberts D, Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinology. 1996;137(7):2990–9.PubMed
51.
go back to reference Sasson S, Gorowits N, Joost HG, King GL, Cerasi E, Kaiser N. Regulation by metformin of the hexose transport system in vascular endothelial and smooth muscle cells. Br J Pharmacol. 1996;117(6):1318–24.PubMedPubMedCentralCrossRef Sasson S, Gorowits N, Joost HG, King GL, Cerasi E, Kaiser N. Regulation by metformin of the hexose transport system in vascular endothelial and smooth muscle cells. Br J Pharmacol. 1996;117(6):1318–24.PubMedPubMedCentralCrossRef
52.
go back to reference Marchetti P, Gregorio F, Benzi L, Giannarelli R, Cecchetti P, Villani G, et al. Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. Diabete Metab. 1990;16(6):473–8.PubMed Marchetti P, Gregorio F, Benzi L, Giannarelli R, Cecchetti P, Villani G, et al. Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. Diabete Metab. 1990;16(6):473–8.PubMed
53.
go back to reference Caillé G, Lacasse Y, Raymond M, Landriault H, Perrotta M, Picirilli G, et al. Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. Biopharm Drug Dispos. 1993;14(3):257–63.PubMedCrossRef Caillé G, Lacasse Y, Raymond M, Landriault H, Perrotta M, Picirilli G, et al. Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. Biopharm Drug Dispos. 1993;14(3):257–63.PubMedCrossRef
54.
55.
go back to reference Radziuk J, Zhang Z, Wiernsperger N, Pye S. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes. 1997;46(9):1406–13.PubMedCrossRef Radziuk J, Zhang Z, Wiernsperger N, Pye S. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes. 1997;46(9):1406–13.PubMedCrossRef
56.
go back to reference Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 500 drugs. Pharmazie. 1997;52(12):895–911.PubMed Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 500 drugs. Pharmazie. 1997;52(12):895–911.PubMed
57.
go back to reference Stith BJ, Woronoff K, Wiernsperger N. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem Pharmacol. 1998;55(4):533–6.PubMedCrossRef Stith BJ, Woronoff K, Wiernsperger N. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem Pharmacol. 1998;55(4):533–6.PubMedCrossRef
58.
go back to reference Lalau JD, Mourlhon C, Bergeret A, Lacroix C. Consequences of metformin intoxication. Diabetes Care. 1998;21(11):2036–7.PubMedCrossRef Lalau JD, Mourlhon C, Bergeret A, Lacroix C. Consequences of metformin intoxication. Diabetes Care. 1998;21(11):2036–7.PubMedCrossRef
59.
go back to reference Lalau JD, Race JM, Brinquin L. Lactic acidosis in metformin therapy. Relationship between plasma metformin concentration and renal function. Diabetes Care. 1998;21(8):1366–7.PubMedCrossRef Lalau JD, Race JM, Brinquin L. Lactic acidosis in metformin therapy. Relationship between plasma metformin concentration and renal function. Diabetes Care. 1998;21(8):1366–7.PubMedCrossRef
60.
go back to reference al-Jebawi AF, Lassman MN, Abourizk NN. Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient. Diabetes Care. 1998;21(8):1364–5.PubMedCrossRef al-Jebawi AF, Lassman MN, Abourizk NN. Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient. Diabetes Care. 1998;21(8):1364–5.PubMedCrossRef
61.
go back to reference Detaille D, Wiernsperger N, Devos P. Potentiating effect of metformin on insulin-induced glucose uptake and glycogen metabolism with Xenopus oocytes. Diabetologia. 1998;41(1):2–8.PubMedCrossRef Detaille D, Wiernsperger N, Devos P. Potentiating effect of metformin on insulin-induced glucose uptake and glycogen metabolism with Xenopus oocytes. Diabetologia. 1998;41(1):2–8.PubMedCrossRef
62.
go back to reference Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57.PubMedCrossRef Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57.PubMedCrossRef
63.
go back to reference Detaille D, Wiernsperger N, Devos P. Cellular and molecular mechanisms involved in insulin’s potentiation of glycogen synthase activity by metformin. Biochem Pharmacol. 1999;58(9):1475–86.PubMedCrossRef Detaille D, Wiernsperger N, Devos P. Cellular and molecular mechanisms involved in insulin’s potentiation of glycogen synthase activity by metformin. Biochem Pharmacol. 1999;58(9):1475–86.PubMedCrossRef
64.
go back to reference Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol. 1999;364(2–3):205–9.PubMedCrossRef Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol. 1999;364(2–3):205–9.PubMedCrossRef
65.
go back to reference Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab. 1999;25(2):110–27.PubMed Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab. 1999;25(2):110–27.PubMed
66.
67.
go back to reference Nelson RW. Oral medications for treating diabetes mellitus in dogs and cats. J Small Anim Pract. 2000;41(11):486–90.PubMedCrossRef Nelson RW. Oral medications for treating diabetes mellitus in dogs and cats. J Small Anim Pract. 2000;41(11):486–90.PubMedCrossRef
68.
go back to reference Sambol NC, Chiang J, O’Conner M, Liu CY, Lin ET, Goodman AM, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996;36(11):1012–21.PubMedCrossRef Sambol NC, Chiang J, O’Conner M, Liu CY, Lin ET, Goodman AM, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996;36(11):1012–21.PubMedCrossRef
69.
go back to reference Desel H, Stedtler U, Behrens A, Neuratz H. Mischintoxikation mit Metformin. Toxichem Krimtech [in German]. 2000;67:4–8. Desel H, Stedtler U, Behrens A, Neuratz H. Mischintoxikation mit Metformin. Toxichem Krimtech [in German]. 2000;67:4–8.
70.
go back to reference Reeker W, Schneider G, Felgenhauer N, Tempel G, Kochs E. Metformin-inducedlactic acidosis [in German]. Dtsch Med Wochenschr. 2000;125:249–51.PubMedCrossRef Reeker W, Schneider G, Felgenhauer N, Tempel G, Kochs E. Metformin-inducedlactic acidosis [in German]. Dtsch Med Wochenschr. 2000;125:249–51.PubMedCrossRef
71.
go back to reference Lipha Pharmaceuticals Inc. Package insert of Glucophage [FDA approved]. France: Lipha Pharmaceuticals Inc.; 1997. Lipha Pharmaceuticals Inc. Package insert of Glucophage [FDA approved]. France: Lipha Pharmaceuticals Inc.; 1997.
72.
go back to reference Lalau JD, Race JM. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab. 2000;2(3):131–7.PubMedCrossRef Lalau JD, Race JM. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab. 2000;2(3):131–7.PubMedCrossRef
73.
go back to reference Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ. Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res. 2000;8(7):530–9.PubMedCrossRef Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ. Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res. 2000;8(7):530–9.PubMedCrossRef
74.
go back to reference Lalau JD, Race JM, Andreelli F, Lacroix C, Canarelli JP. Metformin retention independent of renal failure in intestinal occlusion. Diabetes Metab. 2001;27(1):24–8.PubMed Lalau JD, Race JM, Andreelli F, Lacroix C, Canarelli JP. Metformin retention independent of renal failure in intestinal occlusion. Diabetes Metab. 2001;27(1):24–8.PubMed
76.
go back to reference Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis’. Diabetes Obes Metab. 2001;3(3):195–201.PubMedCrossRef Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis’. Diabetes Obes Metab. 2001;3(3):195–201.PubMedCrossRef
77.
go back to reference Yuan L, Ziegler R, Hamann A. Inhibition of phosphoenolpyruvate carboxykinase gene expression by metformin in cultured hepatocytes. Chin Med J. 2002;115(12):1843–8.PubMed Yuan L, Ziegler R, Hamann A. Inhibition of phosphoenolpyruvate carboxykinase gene expression by metformin in cultured hepatocytes. Chin Med J. 2002;115(12):1843–8.PubMed
78.
go back to reference Lupi R, Del Guerra S, Fierabracci V, Marselli L, Novelli M, Patanè G, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes. 2002;51(Suppl 1):S134–7.PubMedCrossRef Lupi R, Del Guerra S, Fierabracci V, Marselli L, Novelli M, Patanè G, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes. 2002;51(Suppl 1):S134–7.PubMedCrossRef
79.
go back to reference Barrueto F, Meggs WJ, Barchman MJ. Clearance of metformin by hemofiltration in overdose. J Toxicol Clin Toxicol. 2002;40(2):177–80.PubMedCrossRef Barrueto F, Meggs WJ, Barchman MJ. Clearance of metformin by hemofiltration in overdose. J Toxicol Clin Toxicol. 2002;40(2):177–80.PubMedCrossRef
80.
go back to reference Lalau JD, Lacroix C. Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab. 2003;5(2):93–8.PubMedCrossRef Lalau JD, Lacroix C. Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab. 2003;5(2):93–8.PubMedCrossRef
81.
go back to reference Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58(7):447–74.PubMed Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58(7):447–74.PubMed
82.
go back to reference Nisse P, Mathieu-Nolf M, Deveaux M, Forceville X, Combes A. A fatal case of metformin poisoning. J Toxicol Clin Toxicol. 2003;41(7):1035–6.PubMedCrossRef Nisse P, Mathieu-Nolf M, Deveaux M, Forceville X, Combes A. A fatal case of metformin poisoning. J Toxicol Clin Toxicol. 2003;41(7):1035–6.PubMedCrossRef
83.
go back to reference Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471–2.PubMedCrossRef Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471–2.PubMedCrossRef
84.
go back to reference Sweeney D, Raymer ML, Lockwood TD. Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents. Biochem Pharmacol. 2003;66(4):663–77.PubMedCrossRef Sweeney D, Raymer ML, Lockwood TD. Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents. Biochem Pharmacol. 2003;66(4):663–77.PubMedCrossRef
85.
go back to reference Howlett HC, Bailey C. A risk-benefit analysis of metformin in type-2 diabetes mellitus. Drug Saf. 2001;6:489–503. Howlett HC, Bailey C. A risk-benefit analysis of metformin in type-2 diabetes mellitus. Drug Saf. 2001;6:489–503.
86.
go back to reference Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994;30(3):187–228.PubMedCrossRef Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994;30(3):187–228.PubMedCrossRef
87.
go back to reference Moore KA, Levine B, Titus JM, Fowler DR. Analysis of metformin in antemortem serum and postmortem specimens by a novel HPLC method and application to an intoxication case. J Anal Toxicol. 2003;27(8):592–4.PubMedCrossRef Moore KA, Levine B, Titus JM, Fowler DR. Analysis of metformin in antemortem serum and postmortem specimens by a novel HPLC method and application to an intoxication case. J Anal Toxicol. 2003;27(8):592–4.PubMedCrossRef
88.
go back to reference Nelson R, Spann D, Elliott D, Brondos A, Vulliet R. Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats. J Vet Intern Med. 2004;18(1):18–24.PubMedCrossRef Nelson R, Spann D, Elliott D, Brondos A, Vulliet R. Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats. J Vet Intern Med. 2004;18(1):18–24.PubMedCrossRef
89.
go back to reference Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J. 2004;382(Pt 3):877–84.PubMedPubMedCentralCrossRef Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J. 2004;382(Pt 3):877–84.PubMedPubMedCentralCrossRef
90.
go back to reference Feng SY, Lai EP, Dabek-Zlotorzynska E, Sadeghi S. Molecularly imprinted solid-phase extraction for the screening of antihyperglycemic biguanides. J Chromatogr A. 2004;1027(1–2):155–60.PubMedCrossRef Feng SY, Lai EP, Dabek-Zlotorzynska E, Sadeghi S. Molecularly imprinted solid-phase extraction for the screening of antihyperglycemic biguanides. J Chromatogr A. 2004;1027(1–2):155–60.PubMedCrossRef
91.
go back to reference Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255(2):179–87.PubMedCrossRef Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255(2):179–87.PubMedCrossRef
92.
go back to reference Holland W, Morrison T, Chang Y, Wiernsperger N, Stith BJ. Metformin (glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004;67(11):2081–91.PubMedCrossRef Holland W, Morrison T, Chang Y, Wiernsperger N, Stith BJ. Metformin (glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004;67(11):2081–91.PubMedCrossRef
93.
go back to reference Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89(11):5535–41.PubMedCrossRef Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89(11):5535–41.PubMedCrossRef
94.
go back to reference Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes. 2000;49(5):735–40.PubMedCrossRef Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes. 2000;49(5):735–40.PubMedCrossRef
95.
go back to reference Lalau JD, Masmoudi K. Unexpected recovery from prolonged hypoglycemic coma: a protective role of metformin? [letter]. Intensive Care Med. 2005;31(3):493.PubMedCrossRef Lalau JD, Masmoudi K. Unexpected recovery from prolonged hypoglycemic coma: a protective role of metformin? [letter]. Intensive Care Med. 2005;31(3):493.PubMedCrossRef
96.
go back to reference Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54(7):2179–87.PubMedCrossRef Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54(7):2179–87.PubMedCrossRef
97.
go back to reference Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22(2):255–9.PubMedCrossRef Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22(2):255–9.PubMedCrossRef
98.
go back to reference Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110.PubMedCrossRef Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110.PubMedCrossRef
99.
go back to reference Arafat T, Kaddoumi A, Shami M, Yassin M. Pharmacokinetics and pharmacodynamics of two oral formulations of metformin hydrochloride. Adv Ther. 1994;11:21–33. Arafat T, Kaddoumi A, Shami M, Yassin M. Pharmacokinetics and pharmacodynamics of two oral formulations of metformin hydrochloride. Adv Ther. 1994;11:21–33.
100.
go back to reference Brookes LG, Sambol NC, Lin ET, et al. Effect of dosage for dose and food on the pharmacokinetics of metformin [abstract]. Pharm Res. 1991;8(Suppl.):S320. Brookes LG, Sambol NC, Lin ET, et al. Effect of dosage for dose and food on the pharmacokinetics of metformin [abstract]. Pharm Res. 1991;8(Suppl.):S320.
101.
go back to reference Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35(11):1094–102.PubMedCrossRef Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35(11):1094–102.PubMedCrossRef
102.
go back to reference Lacher M, Hermanns-Clausen M, Haeffner K, Brandis M, Pohl M. Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr. 2005;164(6):362–5.PubMedCrossRef Lacher M, Hermanns-Clausen M, Haeffner K, Brandis M, Pohl M. Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr. 2005;164(6):362–5.PubMedCrossRef
103.
go back to reference Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611–7.PubMedCrossRef Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611–7.PubMedCrossRef
104.
go back to reference Friesecke S, Abel P, Kraft M, Gerner A, Runge S. Combined renal replacement therapy for severe metformin-induced lactic acidosis. Nephrol Dial Transplant. 2006;21(7):2038–9.PubMedCrossRef Friesecke S, Abel P, Kraft M, Gerner A, Runge S. Combined renal replacement therapy for severe metformin-induced lactic acidosis. Nephrol Dial Transplant. 2006;21(7):2038–9.PubMedCrossRef
105.
go back to reference Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab. 2006;91(1):225–7.PubMedCrossRef Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab. 2006;91(1):225–7.PubMedCrossRef
106.
go back to reference Del Prato S, Bianchi C, Marchetti P. beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev. 2007;23(7):518–27.PubMedCrossRef Del Prato S, Bianchi C, Marchetti P. beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev. 2007;23(7):518–27.PubMedCrossRef
107.
go back to reference Wessler I, Herschel S, Bittinger F, Kirkpatrick CJ. Release of non-neuronal acetylcholine from the isolated human placenta is affected by antidepressants. Life Sci. 2007;80(24–25):2210–3.PubMedCrossRef Wessler I, Herschel S, Bittinger F, Kirkpatrick CJ. Release of non-neuronal acetylcholine from the isolated human placenta is affected by antidepressants. Life Sci. 2007;80(24–25):2210–3.PubMedCrossRef
108.
go back to reference Prikis M, Mesler EL, Hood VL, Weise WJ. When a friend can become an enemy! Recognition and management of metformin-associated lactic acidosis. Kidney Int. 2007;72(9):1157–60.PubMedCrossRef Prikis M, Mesler EL, Hood VL, Weise WJ. When a friend can become an enemy! Recognition and management of metformin-associated lactic acidosis. Kidney Int. 2007;72(9):1157–60.PubMedCrossRef
109.
go back to reference Galea M, Jelacin N, Bramham K, White I. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. Br J Anaesth. 2007;98(2):213–5.PubMedCrossRef Galea M, Jelacin N, Bramham K, White I. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. Br J Anaesth. 2007;98(2):213–5.PubMedCrossRef
110.
go back to reference Bruijstens LA, van Luin M, Buscher-Jungerhans PM, Bosch FH. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med. 2008;66(5):185–90.PubMed Bruijstens LA, van Luin M, Buscher-Jungerhans PM, Bosch FH. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med. 2008;66(5):185–90.PubMed
111.
go back to reference Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med. 2009;37(7):2191–6.PubMedCrossRef Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med. 2009;37(7):2191–6.PubMedCrossRef
112.
go back to reference Dell’Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD, Morgan BW. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med. 2009;54(6):818–23.PubMedCrossRef Dell’Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD, Morgan BW. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med. 2009;54(6):818–23.PubMedCrossRef
113.
go back to reference Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat. 2009;114(2):387–9.PubMedCrossRef Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat. 2009;114(2):387–9.PubMedCrossRef
114.
go back to reference Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–40.PubMedCrossRef Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–40.PubMedCrossRef
116.
go back to reference Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33(9):727–40.PubMedCrossRef Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33(9):727–40.PubMedCrossRef
117.
118.
go back to reference Kane DA, Anderson EJ, Price JW, Woodlief TL, Lin CT, Bikman BT, et al. Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic Biol Med. 2010;49(6):1082–7.PubMedPubMedCentralCrossRef Kane DA, Anderson EJ, Price JW, Woodlief TL, Lin CT, Bikman BT, et al. Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic Biol Med. 2010;49(6):1082–7.PubMedPubMedCentralCrossRef
119.
go back to reference Frid A, Sterner GN, Löndahl M, Wiklander C, Cato A, Vinge E, Andersson A. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33(6):1291–3.PubMedPubMedCentralCrossRef Frid A, Sterner GN, Löndahl M, Wiklander C, Cato A, Vinge E, Andersson A. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33(6):1291–3.PubMedPubMedCentralCrossRef
120.
go back to reference Giuliani E, Albertini G, Vaccari C, Barbieri A. pH 6.68—surviving severe metformin intoxication. QJM. 2010;103(11):887–90.PubMedCrossRef Giuliani E, Albertini G, Vaccari C, Barbieri A. pH 6.68—surviving severe metformin intoxication. QJM. 2010;103(11):887–90.PubMedCrossRef
121.
go back to reference Protti A, Russo R, Tagliabue P, Vecchio S, Singer M, Rudiger A, et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care. 2010;14(1):R22.PubMedPubMedCentralCrossRef Protti A, Russo R, Tagliabue P, Vecchio S, Singer M, Rudiger A, et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care. 2010;14(1):R22.PubMedPubMedCentralCrossRef
122.
go back to reference Dell’Aglio DM, Perino LJ, Todino JD, Algren DA, Morgan BW. Metformin overdose with a resultant serum pH of 6.59: survival without sequalae. J Emerg Med. 2010;39(1):e77–80.PubMedCrossRef Dell’Aglio DM, Perino LJ, Todino JD, Algren DA, Morgan BW. Metformin overdose with a resultant serum pH of 6.59: survival without sequalae. J Emerg Med. 2010;39(1):e77–80.PubMedCrossRef
123.
go back to reference Sørensen LK. Determination of metformin and other biguanides in forensic whole blood samples by hydrophilic interaction liquid chromatography-electrospray tandem mass spectrometry. Biomed Chromatogr. 2012;26(1):1–5.PubMedCrossRef Sørensen LK. Determination of metformin and other biguanides in forensic whole blood samples by hydrophilic interaction liquid chromatography-electrospray tandem mass spectrometry. Biomed Chromatogr. 2012;26(1):1–5.PubMedCrossRef
124.
go back to reference The International Association of Forensic Toxicologists (TIAFT). Reference blood level list of therapeutic and toxic substances. London: The Association; 1995–2015. http://www.tiaft.org. Accessed 8 Dec 2010. The International Association of Forensic Toxicologists (TIAFT). Reference blood level list of therapeutic and toxic substances. London: The Association; 1995–2015. http://​www.​tiaft.​org. Accessed 8 Dec 2010.
125.
go back to reference Yeung CW, Chung HY, Fong BM, Tsai NW, Chan WM, Siu TS, et al. Metformin-associated lactic acidosis in Chinese patients with type II diabetes. Pharmacology. 2011;88(5–6):260–5.PubMedCrossRef Yeung CW, Chung HY, Fong BM, Tsai NW, Chan WM, Siu TS, et al. Metformin-associated lactic acidosis in Chinese patients with type II diabetes. Pharmacology. 2011;88(5–6):260–5.PubMedCrossRef
126.
go back to reference Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig. 2011;31(6):435–8.PubMedCrossRef Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig. 2011;31(6):435–8.PubMedCrossRef
127.
go back to reference de Oliveira Baraldi C, Lanchote VL, de Jesus Antunes N, de Jesus Ponte Carvalho TM, Dantas Moisés EC, Duarte G, et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol. 2011;67(10):1027–33.PubMedCrossRef de Oliveira Baraldi C, Lanchote VL, de Jesus Antunes N, de Jesus Ponte Carvalho TM, Dantas Moisés EC, Duarte G, et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol. 2011;67(10):1027–33.PubMedCrossRef
128.
go back to reference Correia CS, Bronander KA. Metformin-associated lactic acidosis masquerading as ischemic bowel. Am J Med. 2012;125(5):e9.PubMedCrossRef Correia CS, Bronander KA. Metformin-associated lactic acidosis masquerading as ischemic bowel. Am J Med. 2012;125(5):e9.PubMedCrossRef
129.
go back to reference Vecchio S, Papa P, Protti A. Metformin and lactic acidosis. In: Vincent JL, editor. Annual update in intensive care and emergency medicine, vol. 1. Heidelberg: Springer Science & Business Media; 2011. p. 685–93. Vecchio S, Papa P, Protti A. Metformin and lactic acidosis. In: Vincent JL, editor. Annual update in intensive care and emergency medicine, vol. 1. Heidelberg: Springer Science & Business Media; 2011. p. 685–93.
130.
go back to reference Takiyama Y, Harumi T, Watanabe J, Fujita Y, Honjo J, Shimizu N, Makino Y, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes. 2011;60(3):981–92.PubMedPubMedCentralCrossRef Takiyama Y, Harumi T, Watanabe J, Fujita Y, Honjo J, Shimizu N, Makino Y, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes. 2011;60(3):981–92.PubMedPubMedCentralCrossRef
132.
go back to reference Roche C, Nau A, Peytel E, Moalic JL, Oliver M. Severe lactic acidosis due to metformin: report of 3 cases. Ann Biol Clin (Paris). 2011;69(6):705–11. Roche C, Nau A, Peytel E, Moalic JL, Oliver M. Severe lactic acidosis due to metformin: report of 3 cases. Ann Biol Clin (Paris). 2011;69(6):705–11.
133.
go back to reference Perrone J, Phillips C, Gaieski D. Occult metformin toxicity in three patients with profound lactic acidosis. J Emerg Med. 2011;40(3):271–5.PubMedCrossRef Perrone J, Phillips C, Gaieski D. Occult metformin toxicity in three patients with profound lactic acidosis. J Emerg Med. 2011;40(3):271–5.PubMedCrossRef
134.
go back to reference Pikwer A, Vernersson E, Frid A, Sterner G. Extreme lactic acidosis type B associated with metformin treatment. NDT Plus. 2011;4(6):399–401.PubMedPubMedCentral Pikwer A, Vernersson E, Frid A, Sterner G. Extreme lactic acidosis type B associated with metformin treatment. NDT Plus. 2011;4(6):399–401.PubMedPubMedCentral
135.
go back to reference Cosenza L, Al-Dahir S, Engel LS, Nielsen N. A potentially fatal case of mistaken identity: metformin vs oxycodone-acetaminophen [abstract]. J Investig Med. 2011;59(2):385. Cosenza L, Al-Dahir S, Engel LS, Nielsen N. A potentially fatal case of mistaken identity: metformin vs oxycodone-acetaminophen [abstract]. J Investig Med. 2011;59(2):385.
136.
go back to reference Berstein LM, Yue W, Wang JP, Santen RJ. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat. 2011;128(1):109–17.PubMedCrossRef Berstein LM, Yue W, Wang JP, Santen RJ. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat. 2011;128(1):109–17.PubMedCrossRef
138.
go back to reference Briet C, Saraval-Gross M, Kajbaf F, Fournier A, Hary L, Lalau JD. Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. Clin Kidney J. 2012;5(1):65–7.PubMedPubMedCentralCrossRef Briet C, Saraval-Gross M, Kajbaf F, Fournier A, Hary L, Lalau JD. Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. Clin Kidney J. 2012;5(1):65–7.PubMedPubMedCentralCrossRef
139.
go back to reference Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care. 2012;16(4):R136.PubMedPubMedCentralCrossRef Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care. 2012;16(4):R136.PubMedPubMedCentralCrossRef
140.
go back to reference Protti A, Fortunato F, Monti M, Vecchio S, Gatti S, Comi GP, et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care. 2012;16(3):R75.PubMedPubMedCentralCrossRef Protti A, Fortunato F, Monti M, Vecchio S, Gatti S, Comi GP, et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care. 2012;16(3):R75.PubMedPubMedCentralCrossRef
141.
go back to reference Protti A, Lecchi A, Fortunato F, Artoni A, Greppi N, Vecchio S, et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care. 2012;16(5):R180.PubMedPubMedCentralCrossRef Protti A, Lecchi A, Fortunato F, Artoni A, Greppi N, Vecchio S, et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care. 2012;16(5):R180.PubMedPubMedCentralCrossRef
142.
go back to reference Lam N, Sekhon G, House AA. Metformin-associated lactic acidosis following intentional overdose successfully treated with tris-hydroxymethyl aminomethane and renal replacement therapy. Case Rep Nephrol. 2012;2012:671595.PubMedPubMedCentral Lam N, Sekhon G, House AA. Metformin-associated lactic acidosis following intentional overdose successfully treated with tris-hydroxymethyl aminomethane and renal replacement therapy. Case Rep Nephrol. 2012;2012:671595.PubMedPubMedCentral
143.
go back to reference Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31–43.PubMedCrossRef Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31–43.PubMedCrossRef
144.
go back to reference Duong JK, Furlong TJ, Roberts DM, Graham GG, Greenfield JR, Williams KM, et al. The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis. Drug Saf (Epub 2013 Apr 3). Duong JK, Furlong TJ, Roberts DM, Graham GG, Greenfield JR, Williams KM, et al. The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis. Drug Saf (Epub 2013 Apr 3).
145.
go back to reference Kajbaf F, Lalau JD. The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med. 2013;30(3):345–8.PubMedCrossRef Kajbaf F, Lalau JD. The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med. 2013;30(3):345–8.PubMedCrossRef
146.
go back to reference Luft D, Deichsel G, Schmulling R, et al. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80(4):484–9.PubMed Luft D, Deichsel G, Schmulling R, et al. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80(4):484–9.PubMed
147.
go back to reference Kajbaf F, Lalau JD. The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. BMC Pharmacol Toxicol. 2013;12(14):22.CrossRef Kajbaf F, Lalau JD. The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. BMC Pharmacol Toxicol. 2013;12(14):22.CrossRef
148.
go back to reference Bonsignore A, Pozzi F, Fraternali Orcioni G, Ventura F, Palmiere C. Fatal metformin overdose: case report and postmortem biochemistry contribution. Int J Legal Med. 2014;128(3):483–92.PubMedCrossRef Bonsignore A, Pozzi F, Fraternali Orcioni G, Ventura F, Palmiere C. Fatal metformin overdose: case report and postmortem biochemistry contribution. Int J Legal Med. 2014;128(3):483–92.PubMedCrossRef
149.
go back to reference Al-Abri SA, Hayashi S, Thoren KL, Olson KR. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. Clin Toxicol (Phila). 2013;51(5):444–7.CrossRef Al-Abri SA, Hayashi S, Thoren KL, Olson KR. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. Clin Toxicol (Phila). 2013;51(5):444–7.CrossRef
151.
go back to reference Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2007;47:185–210.PubMedCrossRef Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2007;47:185–210.PubMedCrossRef
152.
go back to reference Vecchio S, Giampreti A, Petrolini VM, Lonati D, Protti A, Papa P, Rognoni C, et al. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol (Phila). 2014;52(2):129–35.CrossRef Vecchio S, Giampreti A, Petrolini VM, Lonati D, Protti A, Papa P, Rognoni C, et al. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol (Phila). 2014;52(2):129–35.CrossRef
153.
go back to reference Moffat AC, Osselton MD, Widdop B, editors. Clarke’s analysis of drugs and poisons. 3rd ed. London: Pharmaceutical Press; 2004. p. 243. Moffat AC, Osselton MD, Widdop B, editors. Clarke’s analysis of drugs and poisons. 3rd ed. London: Pharmaceutical Press; 2004. p. 243.
154.
go back to reference Repetto MR, Repetto M. Tabla de concentraciones de xenobioticos en fluidos humanos como referencia parael diagnostico toxicologico. 2012. http://www.busca-tox.com. Accessed 3 July 2012. Repetto MR, Repetto M. Tabla de concentraciones de xenobioticos en fluidos humanos como referencia parael diagnostico toxicologico. 2012. http://​www.​busca-tox.​com. Accessed 3 July 2012.
155.
go back to reference Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, Lombès M, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes. 2014;63(3):880–91.PubMedCrossRef Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, Lombès M, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes. 2014;63(3):880–91.PubMedCrossRef
156.
go back to reference Launiainen T, Ojanperä I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Test Anal. 2014;6(4):308–16.PubMedPubMedCentralCrossRef Launiainen T, Ojanperä I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Test Anal. 2014;6(4):308–16.PubMedPubMedCentralCrossRef
157.
go back to reference Fremin K, Owen J. Metformin overdose and early renal replacement therapy. Am J Kidney Dis. 2014;63(5):B47. Fremin K, Owen J. Metformin overdose and early renal replacement therapy. Am J Kidney Dis. 2014;63(5):B47.
158.
go back to reference Renehan A. Diabetes treatment and cancer—five years after the ‘breaking news’. Diabetes Voice. 2014;59(1):36–9. Renehan A. Diabetes treatment and cancer—five years after the ‘breaking news’. Diabetes Voice. 2014;59(1):36–9.
159.
go back to reference Adam WR, O’Brien RC. A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. Diabet Med. 2014;31(9):1032–8.PubMedCrossRef Adam WR, O’Brien RC. A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. Diabet Med. 2014;31(9):1032–8.PubMedCrossRef
160.
go back to reference Acquistapace G, Rossi M, Garbi M, Cosci P, Canetta C, Manelli A, et al. Acute metformin intoxication: 2012 experience of Emergency Department of Lodi, Italy. Clin Chem Lab Med. 2014;52(10):1489–97.PubMedCrossRef Acquistapace G, Rossi M, Garbi M, Cosci P, Canetta C, Manelli A, et al. Acute metformin intoxication: 2012 experience of Emergency Department of Lodi, Italy. Clin Chem Lab Med. 2014;52(10):1489–97.PubMedCrossRef
161.
go back to reference Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37(3):876–86.PubMedPubMedCentralCrossRef Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37(3):876–86.PubMedPubMedCentralCrossRef
162.
go back to reference Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299–306.PubMedCrossRef Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299–306.PubMedCrossRef
163.
go back to reference Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, et al. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2014;96(3):370–9.PubMedPubMedCentralCrossRef Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, et al. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2014;96(3):370–9.PubMedPubMedCentralCrossRef
164.
go back to reference Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21(12):837–50.PubMedCrossRef Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21(12):837–50.PubMedCrossRef
165.
go back to reference Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaei S. Global Partnership for Effective Diabetes Management. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res. 2013;10(5):397–409.PubMedCrossRef Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaei S. Global Partnership for Effective Diabetes Management. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res. 2013;10(5):397–409.PubMedCrossRef
166.
go back to reference Watanabe RM. Drugs, diabetes and pharmacogenomics: the road to personalized therapy. Pharmacogenomics. 2011;12(5):699–701.PubMedCrossRef Watanabe RM. Drugs, diabetes and pharmacogenomics: the road to personalized therapy. Pharmacogenomics. 2011;12(5):699–701.PubMedCrossRef
167.
go back to reference Esposito K, Ceriello A, Giugliano D. Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? Endocrine. 2013;44(2):343–5.PubMedCrossRef Esposito K, Ceriello A, Giugliano D. Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? Endocrine. 2013;44(2):343–5.PubMedCrossRef
168.
go back to reference Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med. 2014;19(7):129–36. Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med. 2014;19(7):129–36.
169.
go back to reference Scheen AJ. Personalising metformin therapy: a clinician’s perspective. Lancet Diabetes Endocrinol. 2014;2(6):442–4.PubMedCrossRef Scheen AJ. Personalising metformin therapy: a clinician’s perspective. Lancet Diabetes Endocrinol. 2014;2(6):442–4.PubMedCrossRef
170.
go back to reference Pratley RE, Kuritzky L, Tenzer P. A patient-centered approach to managing patients with type 2 diabetes. Am J Med. 2014;127(11):e15–6.PubMedCrossRef Pratley RE, Kuritzky L, Tenzer P. A patient-centered approach to managing patients with type 2 diabetes. Am J Med. 2014;127(11):e15–6.PubMedCrossRef
171.
go back to reference Cao J, Meng S, Chang E, Beckwith-Fickas K, Xiong L, Cole RN, et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem. 2014;289(30):20435–46.PubMedPubMedCentralCrossRef Cao J, Meng S, Chang E, Beckwith-Fickas K, Xiong L, Cole RN, et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem. 2014;289(30):20435–46.PubMedPubMedCentralCrossRef
172.
go back to reference El-Mir MY, Nogueira V, Fontaine E, Ave´ret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–8.PubMedCrossRef El-Mir MY, Nogueira V, Fontaine E, Ave´ret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–8.PubMedCrossRef
173.
go back to reference Piel S, Ehinger JK, Elmér E, Hansson MJ. Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition. Acta Physiol (Oxf). 2015;213(1):171–80.PubMedCrossRef Piel S, Ehinger JK, Elmér E, Hansson MJ. Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition. Acta Physiol (Oxf). 2015;213(1):171–80.PubMedCrossRef
174.
go back to reference Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446–54.PubMedPubMedCentralCrossRef Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446–54.PubMedPubMedCentralCrossRef
175.
go back to reference Lalau JD, Kajbaf F. Interpreting the consequences of metformin accumulation in an emergency context: impact of the time frame on the blood metformin levels. Int J Endocrinol. 2014;2014:717198.PubMedPubMedCentralCrossRef Lalau JD, Kajbaf F. Interpreting the consequences of metformin accumulation in an emergency context: impact of the time frame on the blood metformin levels. Int J Endocrinol. 2014;2014:717198.PubMedPubMedCentralCrossRef
176.
go back to reference Lalau JD, Azzoug ML, Kajbaf F, Briet C, Desailloud R. Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation. Diabetes Metab. 2014;40(3):220–3.PubMedCrossRef Lalau JD, Azzoug ML, Kajbaf F, Briet C, Desailloud R. Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation. Diabetes Metab. 2014;40(3):220–3.PubMedCrossRef
177.
go back to reference Kajbaf F, Lalau JD, Azzoug M, Lemaire-Hurtel AS, De Broe ME. Metformin therapy at different stages of chronic kidney disease [abstract]. J Am Soc Nephrol. 2014;25(Abstract Edition):76A. Kajbaf F, Lalau JD, Azzoug M, Lemaire-Hurtel AS, De Broe ME. Metformin therapy at different stages of chronic kidney disease [abstract]. J Am Soc Nephrol. 2014;25(Abstract Edition):76A.
Metadata
Title
Therapeutic Concentrations of Metformin: A Systematic Review
Authors
Farshad Kajbaf
Marc E. De Broe
Jean-Daniel Lalau
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 4/2016
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-015-0323-x

Other articles of this Issue 4/2016

Clinical Pharmacokinetics 4/2016 Go to the issue